Azijli, Kaamar <br/><br/>
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jun 2014 
 - 1273-83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-014-2465-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimetabolites--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Caspases--metabolism<br/>Cathepsin B--metabolism<br/>Cell Cycle--drug effects<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>RNA Interference<br/>RNA, Small Interfering--metabolism<br/>TNF-Related Apoptosis-Inducing Ligand--administration & dosage<br/>Thymidylate Synthase--antagonists & inhibitors<br/>Trifluridine--administration & dosage